J Bone Miner Res 35(8):14151423 [DOI] [PubMed] [Google Scholar] 13.Herrou J, Mabilleau G, Lecerf JM, Thomas T, Biver E, Paccou J (2024) Narrative review of effects of Glucagon-Like Peptide-1 Receptor Agonists on bone health in people living with obesity
However, were still very early in understanding who responds well and who doesnt
Common microdosing approaches The following are the common microdosing approaches: Sustained low dose: Some individuals remain indefinitely on the initial starter dose, such as 0.25 mg of semaglutide weekly, and never exceed this dose
What is the lowest effective dose of semaglutide (GLP-1 receptor agonist) for weight loss?
Key Features: Triple receptor agonist: GLP-1, GIP, and glucagon
307 , E644E652 (2014)